Capricor Therapeutics Inc (NASDAQ:CAPR)
| 4.28 Delayed Data As of 3:59pm ET |  -0.12 / -2.73%Today’s Change | 2.81 Today|||52-Week Range 6.58 | +10.88% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $115.0M |
Company Description
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Contact Information
Capricor Therapeutics, Inc. 10865 Road to the Cure San Diego California 90211 |
Employees
Shareholders
| Mutual fund holders | 6.90% |
| Other institutional | 3.99% |
| Individual stakeholders | 2.77% |
Top Executives
| Linda Marbán | President, Chief Executive Officer & Director |
| Anthony Bergmann | Chief Financial Officer |
| Kristi A. H. Elliott | Vice President-Research & Development |
| Karen G. Krasney | Secretary, Executive VP & General Counsel |
| Xavier Avat | Chief Business Officer |
